anyone knows about how to do that?
Thanks!
Thanks!
-
-
No need to do so. The libraries are already extracted by the machine, at least on the SOLiD 4 and SOLiD 3. -
really?I just got one csfasta and qual file including 8 libraries from the core facility. If so, I will ask them tomorrow.Comment
-
Yes, ask them. Let us know what they say. Since the SOLiD has separate runs for the barcode, the F3 and the F5/R3 then these should separate into three different files and into different samples. We get (and give to our customers) files that are named like:
run00165_Stemredo_BC_000738_StemRedo_05.csfasta
run00165_Stemredo_F5-BC_000738_StemRedo_05.csfasta
run00165_Stemredo_F3_000738_StemRedo_05.csfasta
run00165_Stemredo_BC_000739_StemRedo_06.csfasta
run00165_Stemredo_F5-BC_000739_StemRedo_06.csfasta
run00165_Stemredo_F3_000739_StemRedo_06.csfasta
Plus associated qual and stats files; e.g.,
run00165_Stemredo_BC_QV_000738_StemRedo_05.qual
run00165_Stemredo_BC.stats
Note that there are three .csfasta files per sample.
It is possible to merge all data from the samples into one file. But, at the risk of critiquing another core facility, why do so?Comment
-
I'm having the same problem. I have four barcoded samples, but only got one csfasta and qual files. Did the ppl got the solution for the problem from ABI?
Thx!Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment